{"nctId":"NCT00194116","briefTitle":"Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression","startDateStruct":{"date":"2004-09"},"conditions":["Bipolar Disorder"],"count":54,"armGroups":[{"label":"Divalproex Sodium ER","type":"EXPERIMENTAL","interventionNames":["Drug: Divalproex Sodium ER"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Divalproex Sodium ER","otherNames":["Depakote ER"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must give consent to participate in the study and sign and date the IRB approved written informed consent form prior to the initiation of any study procedures\n* Subject must be between the ages of 18 and 70\n* Subject must have a diagnosis of bipolar I or II.\n* Subject must be currently depressed as confirmed by the Mini-International Neuropsychiatric Interview (MINI)\n* Subject must have a baseline Montgomery-Asberg Depression Scale (MADRS) score of \\>19 and Young Mania Rating Scale (YMRS) score of \\<12\n* Women of childbearing potential must be nonpregnant/nonlactating and using adequate contraception if sexually active\n* Subject must not be using any concomitant psychotropic medications during the acute phase except prn benzodiazepines\n\nExclusion Criteria:\n\n* Subjects lacks the capacity to provide informed consent\n* Subject has currently or previously used divalproex or Dvpx-ER\n* Subject is a serious suicide risk or has medically unstable conditions as judged by the investigators\n* Subject has any alcohol, cocaine, or cannabis dependence within 3 months of study entry\n* Subject has any cocaine, hallucinogens, opiates, crystal methamphetamine, or MMDA abuse within 3 months of study entry","healthyVolunteers":true,"sex":"ALL","minimumAge":"16 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS total scores range from 0-60, where higher scores are indicative of more depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.64","spread":"1.49"},{"groupId":"OG001","value":"-5.32","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Change in Young Mania Rating Scale (YMRS) Total Score","description":"YMRS Scores range from 0 to 60 where higher scores are indicative of more mania.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"5.04"},{"groupId":"OG001","value":"-0.46","spread":"3.28"}]}]}]},{"type":"SECONDARY","title":"Change in General Behavior Inventory (GBI) Depression Scale Score","description":"GBI Depression Scale Scores range from 46-184, where higher scores are indicative of more depression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.56","spread":"14.0"},{"groupId":"OG001","value":"0.9","spread":"18.4"}]}]}]},{"type":"SECONDARY","title":"Change in General Behavior Inventory (GBI) Hypomanic/Biphasic Scale Score","description":"GBI Hypomanic/Biphasic Scale scores range from 28-112, where higher scores are indicative of more hypomanic/manic symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"8.3"},{"groupId":"OG001","value":"-6.8","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form Health Survey (SF-36) Physical Component Summary Score","description":"SF-36 Physical Component Summary scores range from 0-100, with a higher score indicating better physical health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"15.7"},{"groupId":"OG001","value":"-4.2","spread":"9.2"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form Health Survey (SF-36) Mental Component Summary Score","description":"SF-36 Mental Component Summary scores range from 0-100, with a higher score indicating better mental health.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"18.4"},{"groupId":"OG001","value":"13.5","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Change in Hamilton Anxiety Rating Scale (HAMA) Total Score","description":"HAMA Scores range from 0 to 56 where higher scores are indicative of more anxiety.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"4.6"},{"groupId":"OG001","value":"-3.5","spread":"7.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":26},"commonTop":["Nausea","Increased Appetite","Fatigue","Diarrhea","Dry Mouth"]}}}